USA-based BioCryst Pharmaceuticals says that it has signed agreements with two additional partners who will exclusively represent its anti-viral peramivir for influenza stockpiling opportunities for territories outside of the USA.
BioCryst's new partners are Merck Serono (part of German drug major Merck KGaA) for Europe, Russia, Canada and Singapore and Jordan-headquartered Hikma Pharmaceuticals for the Middle East and North Africa (MENA) region, excluding Israel. BioCryst and its seven regional partners for peramivir cover all major and the majority of smaller pharmaceutical markets globally.
"Each of these companies has strong commercial infrastructures and established regulatory contacts in their respective territories, making them attractive partners for peramivir within these important markets," said Jon Stonehouse, president and chief executive of BioCryst, adding that the company "has received peramivir emergency use inquiries from
various countries in these regions, and we look forward to working with Merck Serono and Hikma to make peramivir available during the ongoing influenza pandemic."
BioCryst is currently enrolling patients in two peramivir Phase III trials intended to support US regulatory approval for influenza. Approximately 300 study locations are targeted to participate in these studies globally, the firm says.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze